Skip to main content

Table 3 Characteristics of the patient cohort with cirrhosis due to long-term alcohol misuse included in HCC surveillance programs, stratified by liver-related survival (cohort iii)

From: Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases

  Alcoholic cirrhosis (n = 231) Transplant-free survivors (n = 133) Non-survivors* (n = 98) P value
Age at cirrhosis diagnosis (years) 56.5 (12.4) 56.4 (10.8) 56.6 (14.9) .61
Male sex 185 (80.1%) 105 (78.9%) 80 (81.6%) .64
BMI (kg/m2) 27.0 (6.0) 27.0 (5.9) 27.5 (7.0) .07
Diabetes mellitus 70 (30.4%) 38 (28.6%) 32 (32.7%) .50
Ascites 87 (37.4%) 45 (33.8%) 42 (42.9%) .19
Hepatic encephalopathy 23 (10.0%) 9 (6.8%) 14 (14.3%) .056
Child-Pugh score (points) 6 (3) 6 (3) 7 (3) < .001
HCC during follow-up 56 (23.9%) 9 (6.8%) 47 (48.0%) < .001
Survival (years) 5.0 (6.5) 5.0 (7.3) 4.8 (5.0) .78
Liver transplantation 17 (7.4%) 17 (17.5%) NA
Liver-related death 93 (40.4%) 93 (95.9%) NA
Death 98 (100%) NA
HCC-related    44 (44.9%)  
Liver-related    50 (51.0%)  
Extra-hepatic    4 (4.1%)  
ALT (× ULN) 1.0 (1.0) 1.0 (1.0) 1.0 (1.0) .28
AST (× ULN) 2.0 (1.0) 2.0 (1.0) 2.0 (1.5) .99
GGT (× ULN) 4.0 (6.0) 4.0 (6.0) 5.0 (6.0) .45
Bilirubin (μmol/L) 23.0 (35.5) 21.0 (31.0) 33.0 (47.0) .001
Albumin (mg/dL) 36.3 (10.3) 39.0 (9.4) 34.0 (10.1) .001
PT (% of control) 65.0 (30.5) 68.0 (27.0) 57.0 (30.5) < .001
Platelet count (G/L) 123.5 (74) 129.0 (83.0) 114.0 (57.0) .08
CYFRA21-1 (ng/mL) 5.26 (1.75) 4.99 (1.81) 5.58 (1.75) .008
  1. Quantitative measures are shown as median (interquartile range) or as an absolute count (n) and relative frequency (%). Liver transaminases are displayed as a multiple of the upper limit of normal (ULN). Abbreviations: BMI body mass index, HCC hepatocellular carcinoma, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transferase, PT prothrombin time. *Non-survivors include patients who died or received a liver transplantation within the observation period (median follow-up of 73 months)